Flunixin meglumine

Cat. No.: HY-B0386 Purity: 99.71%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Flunixin meglumine is a cyclooxygenase (COX) inhibitor with IC₅₀ values of 0.55 and 3.24 μM for COX-1 and COX-2, respectively. Flunixin meglumine shows anti-inflammatory effects.

For research use only. We do not sell to patients.

Flunixin meglumine Chemical Structure

CAS No. : 42461-84-7

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
1 g	USD 80	In-stock	Estimated Time of Arrival: December 31
5 g		Get quote
10 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Flunixin meglumine:

Flunixin-d₃ Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Purity & Documentation
References
Customer Review

Description

Flunixin meglumine is a cyclooxygenase (COX) inhibitor with IC₅₀ values of 0.55 and 3.24 μM for COX-1 and COX-2, respectively. Flunixin meglumine shows anti-inflammatory effects^[1]^[2].

IC₅₀ & Target^[2]

COX-1

0.55 μM (IC₅₀)

COX-2

3.24 μM (IC₅₀)

In Vitro

flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide (LPS)-induced activity of inducible nitric oxide synthase (iNOS) in RAW 264.7 murine macrophages^[2].
flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide-induced activation of nuclear factor kappa B (NfκB) in RAW 264.7 murine macrophages^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	RAW 264.7 murine macrophages
Concentration:	10, 100, 300, and 1000 μM
Incubation Time:	2 hours
Result:	Inhibited LPS-induced nitric oxide release at concentrations between 100 and 1,000 µM (P=0.01).

In Vivo

Flunixin meglumine (intravenous injection; 1.1 mg/kg; once) treatment inhibits the formation of exudate PGE2 and serum TXB2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male sheep injected with Carrageenan^[1]
Dosage:	1.1 mg/kg
Administration:	Intravenous injection; 1.1 mg/kg; once
Result:	Inhibited Carrageenan-induced exudate PGE2 formation (E_max, 100%, IC₅₀, <0.4 nM) and serum TXB2 generation (E_max, 100%, IC₅₀, 17 nM) for up to 32 h.

Molecular Weight

491.46

Formula

C₂₁H₂₈F₃N₃O₇

CAS No.

42461-84-7

Appearance

Solid

Color

White to off-white

SMILES

CC1=C(C=CC=C1C(F)(F)F)NC(N=CC=C2)=C2C(O)=O.O[C@H]([C@@H](O)CNC)[C@H](O)[C@H](O)CO

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (203.48 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (101.74 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0348 mL	10.1738 mL	20.3475 mL
5 mM	0.4070 mL	2.0348 mL	4.0695 mL
10 mM	0.2035 mL	1.0174 mL	2.0348 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 50 mg/mL (101.74 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.71%

Select Batch:

Data Sheet (276 KB) SDS (393 KB)

COA (248 KB) LCMS (271 KB)

Handling Instructions (2659 KB)

References

[1]. Z Cheng, et al. Measurement of cyclooxygenase inhibition in vivo: a study of two non-steroidal anti-inflammatory drugs in sheep. Inflammation. 1998 Aug;22(4):353-66. [Content Brief]

[2]. Clare E Bryant, et al. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B. Am J Vet Res. 2003 Feb;64(2):211-5. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.0348 mL	10.1738 mL	20.3475 mL	50.8688 mL
	5 mM	0.4070 mL	2.0348 mL	4.0695 mL	10.1738 mL
	10 mM	0.2035 mL	1.0174 mL	2.0348 mL	5.0869 mL
	15 mM	0.1357 mL	0.6783 mL	1.3565 mL	3.3913 mL
	20 mM	0.1017 mL	0.5087 mL	1.0174 mL	2.5434 mL
	25 mM	0.0814 mL	0.4070 mL	0.8139 mL	2.0348 mL
	30 mM	0.0678 mL	0.3391 mL	0.6783 mL	1.6956 mL
	40 mM	0.0509 mL	0.2543 mL	0.5087 mL	1.2717 mL
	50 mM	0.0407 mL	0.2035 mL	0.4070 mL	1.0174 mL
	60 mM	0.0339 mL	0.1696 mL	0.3391 mL	0.8478 mL
	80 mM	0.0254 mL	0.1272 mL	0.2543 mL	0.6359 mL
	100 mM	0.0203 mL	0.1017 mL	0.2035 mL	0.5087 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.